Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin

References

• WangQWangPHMcLachlanCWongPTSimvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian ratsBrain Res200510451–222923315910782
   PubMed Web of Science ®Google Scholar
• GinterESimkoVStatins: the drugs for the 21st century?Bratisl Lek Listy20091101066466820017462
   PubMed Web of Science ®Google Scholar
• Al-AsmariAKUllahZAl-SabaanFTariqMAl-EidAAl-OmaniSFEffect of vitamin D on bioavailability and lipid lowering efficacy of simvastatinEur J Drug Metab Pharmacokinet2015401879424740652
   PubMed Web of Science ®Google Scholar
• HankeyGJWongKSChankrachangSWorking Group on Stroke and Lipids Management in Asia Consensus PanelManagement of cholesterol to reduce the burden of stroke in Asia: consensus statementInt J Stroke20105320921620536617
   PubMed Web of Science ®Google Scholar
• StroesESThompsonPDCorsiniAEuropean Atherosclerosis Society Consensus PanelStatin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and managementEur Heart J201536171012102225694464
   PubMed Web of Science ®Google Scholar
• EbrahimSCasasJPStatins for all by the age of 50 years?Lancet2012380984154554722607823
   PubMed Web of Science ®Google Scholar
• ParkerBACapizziJAGrimaldiASEffect of statins on skeletal muscle functionCirculation201312719610323183941
   PubMed Web of Science ®Google Scholar
• ManciniGBBakerSBergeronJDiagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus ConferenceCan J Cardiol201127563566221963058
   PubMed Web of Science ®Google Scholar
• McFarlandAJAnoopkumar-DukieSAroraDSMolecular mechanisms underlying the effects of statins in the central nervous systemInt J Mol Sci20141511206072063725391045
   PubMed Web of Science ®Google Scholar
• ThavendiranathanPBagaiABrookhartMAChoudhryNKPrimary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trialsArch Intern Med2006166212307231317130382
   PubMedGoogle Scholar
• SpinaESantoroVD’ArrigoCClinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an updateClin Ther20083071206122718691982
   PubMed Web of Science ®Google Scholar
• BottorffMBStatin safety and drug interactions: clinical implicationsAm J Cardiol2006978A27C31C
   PubMed Web of Science ®Google Scholar
• SantosTBaungratzMMHaskelSPBehavioral interactions of simvastatin and fluoxetine in tests of anxiety and depressionNeuropsychiatr Dis Treat2012841342223055736
   PubMed Web of Science ®Google Scholar
• KilicFSOzatikYKaygisizBBaydemirCErolKAcute antidepressant and anxiolytic effects of simvastatin and its mechanisms in ratsNeurosciences (Riyadh)2012171394322246008
   PubMed Web of Science ®Google Scholar
• WangQZenginADengCHigh dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brainExp Neurol2009216113213819100736
   PubMed Web of Science ®Google Scholar
• VijayaCRamanathanMSureshBLipid lowering activity of ethanolic extract of leaves of Aegle marmelos (Linn.) in hyperlipidaemic models of Wistar albino ratsIndian J Exp Biol200947318218519405383
   PubMed Web of Science ®Google Scholar
• EghwrudjakporPOMiyakeHKurisakaMMoriKCentral nervous system bioaminergic responses to mechanical trauma. An experimental studySurg Neurol19913542732792008642
   PubMedGoogle Scholar
• AnsariJDrug interaction and pharmacistJ Young Pharm20102332633121042495
   PubMedGoogle Scholar
• HuMCheungBMTomlinsonBSafety of statins: an updateTher Adv Drug Saf20123313314425083232
   PubMedGoogle Scholar
• AndradeCKumarCBSuryaSCardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failureInt Clin Psychopharmacol201328314515523325305
   PubMed Web of Science ®Google Scholar
• BellostaSCorsiniAStatin drug interactions and related adverse reactionsExpert Opin Drug Saf201211693394622866966
   PubMed Web of Science ®Google Scholar
• GarcíaMJReinosoRFSánchez NavarroAProusJRClinical pharmacokinetics of statinsMethods Find Exp Clin Pharmacol200325645748112949632
   PubMed Web of Science ®Google Scholar
• SchwartzJBEffects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequenceClin Pharmacol Ther200985219820318754003
   PubMed Web of Science ®Google Scholar
• PrueksaritanontTSubramanianRFangXGlucuronidation of statins in animals and humans: a novel mechanism of statin lactonizationDrug Metab Dispos200230550551211950779
   PubMed Web of Science ®Google Scholar
• HoRHKimRBTransporters and drug therapy: implications for drug disposition and diseaseClin Pharmacol Ther200578326027716153397
   PubMed Web of Science ®Google Scholar
• HoltzmanCWWigginsBSSpinlerSARole of P-glycoprotein in statin drug interactionsPharmacotherapy200626111601160717064205
   PubMed Web of Science ®Google Scholar
• KivistöKTNiemiMSchaeffelerELipid-lowering response to statins is affected by CYP3A5 polymorphismPharmacogenetics200414852352515284534
   PubMedGoogle Scholar
• KolarsJCSchmiedlin-RenPSchuetzJDFangCWatkinsPBIdentification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytesJ Clin Invest1992905187118781430211
   PubMed Web of Science ®Google Scholar
• FrommMFBusseDKroemerHKEichelbaumMDifferential induction of prehepatic and hepatic metabolism of verapamil by rifampinHepatology19962447968018855178
   PubMed Web of Science ®Google Scholar
• ItalianoDSpinaEde LeonJPharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressantsExpert Opin Drug Metab Toxicol201410111457148925196459
   PubMed Web of Science ®Google Scholar
• VlaseLNeagMPopaAMunteanDLeucutaSEPharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot studyCurr Ther Res Clin Exp201071636036824688155
   PubMed Web of Science ®Google Scholar
• SagerJELutzJDFotiRSDavisCKunzeKLIsoherranenNFluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Clin Pharmacol Ther201495665366224569517
   PubMed Web of Science ®Google Scholar
• MaxaJLMeltonLBOguCCSillsMNLimanniARhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazoleAnn Pharmacother200236582082311978159
   PubMed Web of Science ®Google Scholar
• KantolaTKivistöKTNeuvonenPJErythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrationsClin Pharmacol Ther19986421771829728898
   PubMed Web of Science ®Google Scholar
• KanathurNMathaiMGByrdRPJrFieldsCLRoyTMSimvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitisTenn Med200194933934111550401
   PubMedGoogle Scholar
• JerlingMHuanBLLeungKChuNAbdallahHHusseinZStudies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjectsJ Clin Pharmacol200545442243315778423
   PubMed Web of Science ®Google Scholar
• LiljaJJKivistöKTNeuvonenPJGrapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitorsClin Pharmacol Ther19986454774839834039
   PubMed Web of Science ®Google Scholar
• AmchinJEreshefskyLZarycranskiWTaylorKAlbanoDKlockowskiPMEffect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probeJ Clin Pharmacol200141444345111304901
   PubMed Web of Science ®Google Scholar
• ZhouSFXueCCYuXQLiCWangGClinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoringTher Drug Monit200729668771018043468
   PubMed Web of Science ®Google Scholar
• BartheLWoodleyJHouinGGastrointestinal absorption of drugs: methods and studiesFundam Clin Pharmacol199913215416810226759
   PubMed Web of Science ®Google Scholar
• HolickMFVitamin D deficiencyN Engl J Med2007357326628117634462
   PubMed Web of Science ®Google Scholar
• WeissJDormannSMMartin-FacklamMKerpenCJKetabi-KiyanvashNHaefeliWEInhibition of P-glycoprotein by newer antidepressantsJ Pharmacol Exp Ther2003305119720412649369
   PubMed Web of Science ®Google Scholar
• ChristiansUStromTZhangYLActive drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamicsTher Drug Monit2006281394416418692
   PubMed Web of Science ®Google Scholar
• ChanLMLowesSHirstBHThe ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailabilityEur J Pharm Sci2004211255114706810
   PubMed Web of Science ®Google Scholar
• KarlgrenMVildhedeANorinderUClassification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactionsJ Med Chem201255104740476322541068
   PubMed Web of Science ®Google Scholar
• Nałęcz-JaweckiGEvaluation of the in vitro biotransformation of fluoxetine with HPLC, mass spectrometry and ecotoxicological testsChemosphere2007701293517764718
   PubMed Web of Science ®Google Scholar
• VeveraJValešKFišarZThe effect of prolonged simvastatin application on serotonin uptake, membrane microviscosity and behavioral changes in the animal modelPhysiol Behav201615811212026917054
   PubMed Web of Science ®Google Scholar
• ElBatshMMAntidepressant-like effect of simvastatin in diabetic ratsCan J Physiol Pharmacol201593864965626120891
   PubMed Web of Science ®Google Scholar
• BymasterFPZhangWCarterPAFluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortexPsychopharmacology (Berl)2002160435336111919662
   PubMed Web of Science ®Google Scholar
• DrydenSBrownMKingPWilliamsGDecreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetineHorm Metab Res199931636336610437624
   PubMed Web of Science ®Google Scholar
• O’KaneMWilesPGWalesJKFluoxetine in the treatment of obese type 2 diabetic patientsDiabet Med19941111051108181239
   PubMed Web of Science ®Google Scholar
• DaubresseJCKolanowskiJKrzentowskiGKutnowskiMScheenAVan GaalLUsefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter studyObes Res1996443913968822764
   PubMedGoogle Scholar